Demonstration venue · read-only. Every page can be browsed; the buttons that would change it are switched off. Create an account to run TaxoReview on your own data. A simulation from public publication records: the people listed were not invited and did not agree to review.
? Tutorial for this page

Xingqi Hui

dblp:423/0329 · DBLP profile ↗
← Back
1ranked-venue papers
0as first author
1since 2021 · last 2025
—ORCID · none

Domains — the database's venue-derived domains; a paper can count in several

Applied, interdisciplinary, general and emerging computing · 1 · 1 since 2021

Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.

Interdisciplinary, comprehensive, and emerging computing
1 paper
Bioinformatics and computational biology · 75% Medical and health informatics · 25%

Topics — the 4 heaviest of 5, each with the papers that count most for it

TopicWeightPapersLastEvidence papers
Medical and health informatics
drug development
0.912025
AI in drug development: advances in response, combination therapy, repositioning, and molecular design · Sci. China Inf. Sci. 2025
Bioinformatics and computational biology › drug discovery
drug repositioning
0.912025
AI in drug development: advances in response, combination therapy, repositioning, and molecular design · Sci. China Inf. Sci. 2025
Bioinformatics and computational biology › drug discovery
drug response prediction
0.912025
AI in drug development: advances in response, combination therapy, repositioning, and molecular design · Sci. China Inf. Sci. 2025
Bioinformatics and computational biology › molecular informatics
molecular design
0.912025
AI in drug development: advances in response, combination therapy, repositioning, and molecular design · Sci. China Inf. Sci. 2025

Methods — techniques the papers use, named apart from their topics

artificial intelligence · 0.9
YearPublicationVenuePosition
2025 AI in drug development: advances in response, combination therapy, repositioning, and molecular design
Ren Qi, Shujia Liu, Xingqi Hui, Alexey K. Shaytan
Sci. China Inf. Sci.3